Pricing Log in Create free account
Saturday 7 November 2026 Export PETS’s income statement to Excel — free account

PetMed Express, Inc.

PETS Healthcare Pharmaceutical Retailers

PetMed Express, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $179.0 million, down 21.1% from fiscal 2025.

Revenue
−19.9%
EPS
+83.0%
Free cash flow
+38.6%

Quarter to June 2026, against a year earlier

1.22 0.02 −1.61%
Market cap
$26.9M
P/E
0.0×
Fwd P/E
−2.4×
Dividend yield
—
F-score
3/9
Altman Z
0.40
Beneish M
−4.77
Dividend safety
36/100
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 0.04
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — 1 — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 33.63%

Capital & Financial Ratios $m

Size
Market Cap 26.88
Revenue ttm 168.86
Net income ttm (29.28)
Free cash flow ttm (27.77)
Net debt Q (13.08)
Valuation
P/E 0.00
Forward P/E (2.44) (negative: loss-making)
Price / sales 0.16
Forward P/S Powerpack
Price / FCF 0.00
Price / book 1.14
Financial health
Current ratio Q 0.68 (below 1: weak)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q —
Growth
Revenue growth Q −19.86% (below 0%: shrinking)
Operating income growth Q +81.74% (above 0%: growing)
EPS, this year +81.75% (at or above 15%: strong)
EPS, next year A +30.00% (at or above 15%: strong)
Revenue, next year A −16.66% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A +49.64% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 0.1×, against a ten-year median of 1.3×; over the ten years it ranged from 0.0× in 2025 to 3.5× in 2017.
P/S against its own 10 years 0.51%
10-year low 10-year high
P/B against its own 10 years 13.82%
10-year low 10-year high
EV/Sales against its own 10 years 2.98%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—
Growth, 2017–25
−100.0%/yr
  1. 0.79 ’17
  2. 1.04 ’18 +32
  3. 1.08 ’19 +4
  4. 1.11 ’20 +3
  5. 1.18 ’21 +6
  6. 1.20 ’22 +2
  7. 0.90 ’23 −25
  8. 0.00 ’24 −100
  9. 0.00 ’25
paid change on the year, % Powerpack

Assets vs Liabilities $m

2024 2025 2026 Q'26
Cash 55 55 21 13
Receivables 3 2 2 2
Inventory 29 16 14 8
Other — — — —
94 79 44 28
2024 2025 2026 Q'26
Payables 37 24 21 12
ST’ Debt — — — —
Other — — — —
72 63 52 41

Compound Annual Growth %

10y 5y 3y
Sales (2.67%) (10.02%) (10.24%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (10.02%) (27.17%) (35.92%)

Earnings Trends EPS, adjusted, against the consensus

Q1 FY27 Estimate 0.12 Actual −0.28

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q2 FY26 0.04 −0.41 Miss by 0.45
Q3 FY26 −0.06 −0.50 Miss by 0.44
Q4 FY26 −0.18 −0.19 Miss by 0.01
Q1 FY27 0.12 −0.28 Miss by 0.40
Q2 FY27 −0.11 — Reports 10 November 2026

EPS $

Jun Sep Dec Mar Year
’26 (0.28) — — — —
’26 (1.65) (0.41) (0.50) (0.19) (2.74)
’25 0.18 0.11 (0.03) (0.56) (0.30)
’24 (0.06) 0.03 (0.10) (0.25) (0.37)
’23 0.14 0.13 (0.01) (0.01) 0.25
’22 0.22 0.31 0.21 0.18 0.92
’21 0.39 0.42 0.38 0.01 1.19
Fiscal quarters ending in the months shown.

Revenue $m

Jun Sep Dec Mar Year
’26 41 — — — —
’26 51 44 41 43 179
’25 66 58 52 51 227
’24 78 71 65 60 274
’23 70 65 59 53 248
’22 79 67 61 65 272
’21 96 75 66 66 304
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Jun Sep Dec Mar Year
’26 (8) — — — —
’26 (12) (2) (9) (5) (28)
’25 (9) 7 (1) 7 5
’24 1 (1) (3) 7 4
’23 6 (1) 13 10 28
’22 0 1 9 9 18
’21 (11) 26 6 18 40
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Jun Sep Dec Mar Year
’26 (8) — — — —
’26 (14) (5) (9) (5) (33)
’25 (9) 6 (2) 5 0
’24 (1) (2) (4) 6 0
’23 5 (3) 12 8 23
’22 (1) 1 8 8 17
’21 (11) 25 6 18 38
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

5
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to March

Ten-year view Analyst estimates Powerpack
Group Line 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 TTM Jun ’26 Trend 10 yrs 2027e 2028e 2029e Next 3/yr
Income, $m
Income, $m Revenue 249 274 283 284 304 272 248 274 227 179 169 (3.6%) 149 153 157 (4.3%)
Gross margin, % 31.83 35.72 33.63 28.60 27.77 28.26 30.90 30.93 30.46 28.05 27.92 (3.8) pt
EBT 38 54 49 34 31 24 7 (6) (1) (57) (29) n/m
EBT margin, % 15.22 19.65 17.33 11.93 10.19 8.88 3.01 (2.29) (0.26) (32.04) (17.38) (47.3) pt
Net income 24 37 38 26 24 19 5 (7) (6) (57) (29) n/m
Per share, $
Per share, $ Revenue 12.32 13.46 13.85 14.18 15.13 13.50 12.21 13.44 11.02 8.56 7.79 (4.0%)
Earnings 1.18 1.83 1.84 1.29 1.19 0.93 0.25 (0.37) (0.30) (2.74) (1.38) n/m
Cash flow 2.33 1.84 2.21 1.94 2.00 0.92 1.37 0.21 0.23 (1.36) (1.10) n/m
Capex (0.52) (0.03) (0.03) (0.12) (0.12) (0.09) (0.26) (0.22) (0.25) (0.22) (0.18) (9.2%)
Free cash flow 1.81 1.80 2.18 1.82 1.88 0.83 1.11 (0.01) (0.02) (1.58) (1.28) n/m
Book value 4.61 5.69 6.58 6.49 7.04 6.12 5.42 4.74 4.13 1.38 1.06 (12.5%)
Shares, m 20 20 20 20 20 20 20 20 21 21 21 +0.4%
Valuation, ×
Valuation, × P/E 17.07 22.40 12.50 22.48 29.42 27.98 65.38 0.00 0.00 0.00 0.00 19.7
P/S 1.64 3.06 1.67 2.03 2.32 1.91 1.33 0.35 0.38 0.27 0.16 1.5
P/B 4.36 7.25 3.51 4.44 5.00 4.22 2.99 0.99 1.01 1.65 1.14 3.5
EV/Sales 1.40 2.78 1.31 1.66 1.93 1.50 0.91 0.15 0.14 0.15 0.08 1.2
EV/FCF 9.53 20.74 8.37 12.95 15.59 24.45 9.99 (207.00) (79.94) (0.80) (0.47) (18.6)
Cash, $m
Cash, $m Operating cash flow 47 37 45 39 40 18 28 4 5 (28) (24) n/m
Capex (11) (1) (1) (2) (2) (2) (5) (5) (5) (5) (4) (8.8%)
Free cash flow 37 37 45 37 38 17 23 0 0 (33) (28) n/m
Balance, $m
Balance, $m Working capital 63 87 108 105 116 95 73 21 16 (8) (13) n/m
Net debt (59) (78) (101) (104) (119) (111) (104) (55) (55) (21) (13) (10.6%)
Shareholders’ equity 93 116 135 130 141 123 110 97 85 29 23 (12.2%)
Returns, %
Returns, % ROA 23.46 30.11 26.09 16.69 13.95 10.19 2.96 (4.42) (3.94) (49.84) (33.73) (73.3) pt
ROIC 67.64 86.22 84.50 73.76 84.57 122.73 64.32 (12.31) (3.14) (487.12) (194.08) (554.8) pt
ROE 26.98 35.66 30.14 19.53 17.63 14.14 4.40 (7.22) (6.90) (100.45) (78.58) (127.4) pt
People
People Employees 187 187 199 214 219 212 302 287 173 189 — +0.1%
Revenue/emp, $m 1.33 1.46 1.42 1.33 1.39 1.28 0.82 0.96 1.31 0.95 — (3.7%)
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Mar 2026 · latest quarter Jun 2026 · fundamentals updated 25 Oct 2026

PetMed Express, Inc. vs peers in Pharmaceutical Retailers (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
HITI High Tide Inc. $234.4M — (loss-making) 23.4× +30.72% (above 0%: growing) +800.00% (above 0%: growing) −7.91% (below 0%: shrinking) 26.53% 4.38% Compare
PETS PetMed Express, Inc. $26.9M — (loss-making) — (loss-making) −19.86% (below 0%: shrinking) n/m +38.60% (above 0%: growing) 27.63% (15.19%)
POM Pomdoctor Limited - Sponsored ADR $11.6M — — — — — — — Compare
SCNX Scienture Holdings, Inc. $5.1M — (loss-making) — (loss-making) +3,235.92% (above 0%: growing) n/m −53.98% (below 0%: shrinking) 97.73% (785.71%) Compare
RDGT Ridgetech Inc. $2.7M — (loss-making) — (loss-making) +113.14% (above 0%: growing) n/m +4,848.31% (above 0%: growing) 22.81% 0.00% Compare
Median of peers $8.3M — — +113.14% — −7.91% 26.53% 0.00%

All 5 Pharmaceutical Retailers stocks →

Pay and ownership Proxy statement filed 25 June 2026

Ownership

Directors and executive officers, together 1.30%
Nina Capital Holdings Inc. 12.20%
SilverCape Investments Limited 12.10%
Renaissance Technologies LLC 5.60%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

PetMed Express, Inc. (PETS) Latest News

2 Oct

Impact 4 · · GlobeNewswire

21 Sep

Impact 3 ·

17 Sep

Impact 3 ·

20 Aug

Impact 3 · · The Motley Fool transcript

14 Aug

Impact 3 ·
Impact 3 · transcript

13 Aug

Impact 4 · · Moby transcript
Impact 3 ·
Impact 3 ·

14 Jul

Impact 3 ·

30 Jun

Impact 4 ·

29 Jun

Impact 4 ·

5 Jun

Impact 3 · · Zacks transcript

3 Jun

Impact 3 · · Moby transcript
Impact 3 · · GuruFocus.com transcript

2 Jun

Impact 4 · · GlobeNewswire
Impact 3 · · The Motley Fool transcript

22 Apr

Impact 4 · · GlobeNewswire

12 Feb

Impact 4 · · ACCESS Newswire

19 Dec

Impact 3 · · Associated Press FinanceMT NewswiresMT NewswiresAssociated Press Finance
Impact 3 · · Associated Press FinanceMT NewswiresMT NewswiresAssociated Press Finance

16 Dec

Impact 4 · · Business Wire

12 Dec

Impact 3 · · Simply Wall St.

11 Dec

Impact 3 · · MT Newswires
Impact 3 · · Associated Press Finance
Impact 3 · · GlobeNewswire

26 Nov

Impact 3 · · GlobeNewswireMT Newswires24/7 Wall St.MT NewswiresMT Newswires

11 Nov

Impact 3 · · Simply Wall St.

20 Oct

Impact 3 · · GlobeNewswire

14 Oct

Impact 3 · · GlobeNewswireStockStoryGuruFocus.comInsider MonkeyFastCompany
stockrow.com/PETS · Data as of Oct 25, 2026 · For information only; not investment advice. · © 2026 stockrow.com